Untapped potential: recognising CNS opportunities in early oncology drug development
Mené en Corée sur 127 patients atteints d'un cancer du poumon non à petites cellules EGFR+ de stade avancé, cet essai de phase I/II évalue la dose maximale tolérée et l'efficacité, du point de vue du taux de réponse objective, du lazertinib, un inhibiteur de tyrosine kinase de l'EGFR de troisième génération, après l'échec d'un traitement par inhibiteur de tyrosine kinase de l'EGFR de première ou de seconde génération
In The Lancet Oncology, Myung-Ju Ahn and colleagues describe what, at first glance, appears to be a standard phase 1–2 study of a novel third-generation EGFR tyrosine kinase inhibitor, lazertinib. In thoracic oncology, third- generation EGFR inhibitors are characterised by their ability to inhibit not only the standard sensitising EGFR mutations occurring in non-small-cell lung cancer (NSCLC), but also T790M, an exon 20 point mutation, which commonly emerges as a resistance mechanism during treatment with first-generation or second- generation inhibitors. Osimertinib, another third-generation inhibitor, is already approved by the US Food and Drug Administration for use in the presence of a detectable T790M mutation after first-generation or second-generation inhibitor therapy, and as first-line therapy, before acquired resistance has emerged.
The Lancet Oncology , commentaire, 2018